LONDON, July 23 GlaxoSmithKline has seen
"very significant" interest from mid-sized pharmaceutical
companies and private equity firms in acquiring a range of older
drugs that it plans to divest, the drugmaker's chief executive
said on Wednesday.
Andrew Witty said he hoped to sell the portfolio of mature
drugs, known as established products, by the end of the year.
Reuters reported exclusively on Tuesday that Indian generics
firm Lupin, some U.S. drugmakers looking for a
tax-saving deal in Europe and private equity funds were all
planning to bid for the assets, which have together have annual
sales of around 1 billion pounds ($1.70 billion).
GSK is only planning to sell the rights to established
products in North America and Western Europe. It plans to retain
them in emerging markets and Japan.
($1 = 0.5870 British Pounds)
(Reporting by Ben Hirschler; Editing by Kate Kelland)